Mary Gospodarowicz

Radiation Oncologist

Radiation Oncology

Princess Margaret Cancer Centre

Location Canada, Toronto

Linkedin

X

Professor Mary Gospodarowicz OC is one of the world’s most distinguished radiation oncologists and a towering figure in global cancer control. Born in Gdańsk, Poland, she immigrated to Canada and graduated from the University of Toronto Faculty of Medicine, going on to spend her entire career at Princess Margaret Cancer Centre and the University of Toronto, where she holds the rank of University Professor — the institution’s highest academic designation. Over a career spanning more than four decades, Prof. Gospodarowicz has made transformative contributions to cancer staging through her leadership of the UICC TNM classification system, shaped clinical trial methodology in radiation oncology, and championed global equitable access to radiotherapy. In 2012 she became the first Canadian and the first woman to serve as President of the Union for International Cancer Control (UICC). She is a recipient of the Order of Canada, the ASTRO Gold Medal, the ESTRO Lifetime Achievement Award, and many other international honors that reflect her impact across clinical care, research, education, and global health leadership.

Current Positions

  • University Professor (highest academic rank), University of Toronto
  • Professor, Department of Radiation Oncology, University of Toronto
  • Consultant Staff, Princess Margaret Hospital / University Health Network, Toronto
  • Chair, Prognostic Factors and TNM Process Task Force, International Union Against Cancer (UICC)
  • Member, Board of Directors, International Extranodal Lymphoma Study Group
  • Member, Board of Directors, City Cancer Challenge Foundation

Education

  • Medical studies (partial), Poland
  • MD, University of Toronto Faculty of Medicine, 1971
  • FRCPC, Fellowship in Radiation Oncology, Royal College of Physicians and Surgeons of Canada
  • FRCR(Hon), Honorary Fellowship, Royal College of Radiologists, United Kingdom

Professional Experience

  • Chair, Genitourinary Trial Committee, National Cancer Institute of Canada (NCIC) Clinical Trials Group — early career leadership role
  • Chair, Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network
  • Medical Director, Princess Margaret Cancer Centre, University Health Network — past
  • Professor and University Professor, Department of Radiation Oncology, University of Toronto — present
  • President, Union for International Cancer Control (UICC), 2012 (first Canadian and first woman to hold this position)
  • Chair, Prognostic Factors and TNM Process Task Force, UICC — present
  • Member, Board of Directors, International Extranodal Lymphoma Study Group — present
  • Member, Board of Directors, City Cancer Challenge Foundation — present

Research Activity

  • Cancer staging and the TNM classification: The defining work of Prof. Gospodarowicz’s career. She has led the UICC’s Prognostic Factors and TNM Process Task Force for decades, overseeing the development and continuous improvement of the international TNM Classification of Malignant Tumours across multiple editions (6th, 7th, 8th). The 7th edition (Sobin, Gospodarowicz, Wittekind, 2009) has accumulated over 28,000 citations, making it one of the most highly cited works in oncology. Her work on the TNM process has been foundational to international consistency in cancer staging and prognostication.
  • Prognostic factors in cancer: Co-editor of the landmark Prognostic Factors in Cancer reference work; led the UICC framework for classifying and applying prognostic factors in clinical oncology; co-authored foundational papers on prognostic factor taxonomy, patient management scenarios, and the role of staging in evidence-based medicine.
  • Genitourinary oncology: Extensive clinical research in testicular cancer (seminoma and non-seminomatous germ cell tumors), bladder cancer, and prostate cancer. Pioneer of surveillance strategies for stage I testicular seminoma; principal investigator on landmark NCIC phase III trials including PR.3 (hormone therapy versus hormones plus pelvic RT in locally advanced prostate cancer) and PR.7 (intermittent vs. continuous androgen suppression), both published in The Lancet and New England Journal of Medicine.
  • Lymphoma: Prolific research on extranodal lymphomas in collaboration with the International Extranodal Lymphoma Study Group; contributed to landmark studies of primary testicular lymphoma, MALT lymphoma, Hodgkin lymphoma treatment and second cancers, and gastrointestinal lymphoma.
  • Second malignancies following cancer treatment: Key contributor to population-based studies quantifying second cancer risks in survivors of testicular cancer, Hodgkin lymphoma, and non-Hodgkin lymphoma, including highly cited studies in JAMA, JNCI, Journal of Clinical Oncology, and New England Journal of Medicine.
  • Global access to radiotherapy: A founding voice in the global radiotherapy access movement; co-author of The Lancet Oncology Commission on expanding global access to radiotherapy (2015), the Nature Cancer perspectives on harnessing radiotherapy for global cancer control (2023), and multiple white papers and global task force reports; champion of equitable cancer care in low- and middle-income countries through the UICC, City Cancer Challenge Foundation, and related initiatives.
  • Image-guided radiotherapy (IGRT): Pioneer of image-guided precision radiotherapy at Princess Margaret Hospital; contributed to foundational studies on cone-beam CT, prostate localization, and dose escalation using IGRT in prostate cancer.
  • NCIC Clinical Trials Group: Long-standing contributor to cooperative group clinical trial research; chair of the genitourinary trial committee; major investigator on phase II and phase III trials in prostate cancer, bladder cancer, and lymphoma.

Honors and Awards

  • Order of Canada (OC) — for contributions to improved cancer radiotherapy and leadership in advancing cancer care worldwide
  • ASTRO Gold Medal, American Society for Radiation Oncology, 2020
  • ASTRO Distinguished Member Award, 2014 — for outstanding contributions to radiation oncology in research, clinical care, teaching, and service
  • ESTRO Lifetime Achievement Award, European Society for Radiotherapy and Oncology
  • Janeway Medal, American Radium Society, 2013
  • O. Harold Warwick Prize, Canadian Cancer Society Research Institute, 2016
  • University Professor, University of Toronto (highest academic rank), 2017
  • Women Who Conquer Cancer Mentorship Award, Conquer Cancer Foundation, 2017
  • CMA May Cohen Award for Women Mentors, Canadian Medical Association, 2012
  • Inaugural Professional Development and Continuing Medical Education Award, University of Toronto Department of Radiation Oncology, 2003
  • First Canadian and first woman to serve as President, Union for International Cancer Control (UICC), 2012

Memberships / Affiliations

  • Fellow of the American Society of Clinical Oncology (FASCO)
  • Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC), Radiation Oncology
  • Honorary Fellow of the Royal College of Radiologists, UK (FRCR(Hon))
  • Union for International Cancer Control (UICC) — Past President (2012); Chair, Prognostic Factors and TNM Process Task Force
  • International Extranodal Lymphoma Study Group — Board of Directors
  • City Cancer Challenge Foundation — Board of Directors
  • NCIC Clinical Trials Group — past member and genitourinary trial committee chair
  • American Society for Radiation Oncology (ASTRO)
  • European Society for Radiotherapy and Oncology (ESTRO)

Areas of Specialization

  • Radiation oncology — genitourinary cancers, lymphoma, global oncology
  • Cancer staging and the TNM classification system
  • Prognostic factors and clinical decision-making in oncology
  • Testicular cancer (seminoma, NSGCT), bladder cancer, prostate cancer
  • Lymphoma (Hodgkin lymphoma, extranodal lymphomas, MALT lymphoma, testicular lymphoma)
  • Image-guided radiotherapy (IGRT) and precision radiation delivery
  • Global access to radiotherapy and cancer care in low- and middle-income countries
  • Second malignancies in cancer survivors
  • Clinical trials in radiation oncology
  • Cancer control policy and leadership

Publications

Prof. Gospodarowicz has authored and co-authored publications in The Lancet, The Lancet Oncology, Nature Medicine, Nature Cancer, New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Journal of the National Cancer Institute, Blood, Annals of Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology Biology Physics, and numerous other leading journals, as well as multiple foundational reference books and editions of the TNM classification.

Select Key Publications:

Sobin LH, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours, 7th edition. John Wiley & Sons, 2009/2011. 28,000+ citations.

Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours, 8th edition. Wiley-Blackwell, 2017.

Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. “The process for continuous improvement of the TNM classification.” Cancer, 2004.

O’Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, Gospodarowicz MK, et al. “The TNM classification of malignant tumours—towards common understanding and reasonable expectations.” The Lancet Oncology 18(7):849–851, 2017.

Brierley J, O’Sullivan H, Asamura H, Byrd D, Huang SH, Lee A, Piñeros M, Gospodarowicz MK, et al. “Global Consultation on Cancer Staging: promoting consistent understanding and use.” Nature Reviews Clinical Oncology 16(12):763–771, 2019.

Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, Hanna TP, Gospodarowicz MK, et al. “Expanding global access to radiotherapy.” The Lancet Oncology 16(10):1153–1186, 2015.

Jaffray DA, Knaul F, Baumann M, Gospodarowicz MK. “Harnessing progress in radiotherapy for global cancer control.” Nature Cancer 4(9):1228–1238, 2023.

Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz MK, et al. “Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.” The Lancet 378(9809):2104–2111, 2011.

Crook JM, O’Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Gospodarowicz MK, et al. “Intermittent androgen suppression for rising PSA level after radiotherapy.” New England Journal of Medicine 367(10):895–903, 2012.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, et al. “ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma.” New England Journal of Medicine 366(5):399–408, 2012.

Travis LB, Hill DA, Dores GM, Gospodarowicz MK, van Leeuwen FE, et al. “Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.” JAMA 290(4):465–475, 2003.

Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. “Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation: the National Cancer Institute of Canada Clinical Trials Group.” Journal of Clinical Oncology 14(11):2901–2907, 1996.

Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. “Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome.” Journal of Clinical Oncology 21(22):4157–4164, 2003.

Book Chapters and Reference Works:

  • Gospodarowicz MK, Dare A, Jaffray DA. “Cancer surgery: orchestrating cancer control by strengthening health systems.” The Lancet Oncology 24(12):1297–1298, 2023.
  • Brierley J, O’Sullivan B, Gospodarowicz MK. “The Expanding Demand for Data in Cancer Control.” In: Cancer Systems and Control for Health Professionals, 2025.
  • Giannopoulos E, Gospodarowicz MK, Pramesh CS. “Cancer Centres: A Nexus for Modern Comprehensive Cancer Care and Control.” In: Cancer Systems and Control for Health Professionals, 2025.
  • Jaffray DA, Gospodarowicz MK, et al. (eds). TNM Classification of Malignant Tumours, multiple editions, Wiley-Blackwell.

All information is sourced from publicly available materials.